Patents by Inventor Chengbiao Wu

Chengbiao Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITION AND METHOD FOR TREATING NEUROPATHY
    Publication number: 20230287072
    Abstract: The present disclosure provides a method of delivery, treatment, and prevention of neuropathy and/or pain associated with NGF treatment for an underline disease or condition with a NGF mutant, such as NGFR100W, that does not elicit pain. The present disclosure further provides a composition of micro- and/or nano-rods attached with the NGF mutant, such as NGFR100W, which are injectable or administered to a target for desired therapies.
    Type: Application
    Filed: August 2, 2021
    Publication date: September 14, 2023
    Applicants: The Regents of the University of California, The Steadman Clinic & Steadman Philippon Research Institute
    Inventors: Chengbiao WU, Kijung SUNG, Chelsea Shileds BAHNEY, Kevin RIVERA, Tejal DESAI
  • PAINLESS NGF FOR FRACTURE REPAIR
    Publication number: 20220152152
    Abstract: The present disclosure is related to methods for stimulating bone fracture healing, comprising administering a pharmaceutical composition comprising biomaterial carriers comprising painless nerve growth factor (NGF).
    Type: Application
    Filed: November 17, 2021
    Publication date: May 19, 2022
    Inventors: Chelsea BAHNEY, Tejal DESAI, Kevin RIVERA, Chengbiao WU
  • Use of GPR30 receptor ligands to mediate neurotrophic action
    Patent number: 6444420
    Abstract: Neurological dysfunction is prevented or treated by the administration of ligands that activate the GPR30 receptor. Ligands include estrogens and structurally related molecules. Preferably the GPR30 ligand is an orally available drug that can cross into the brain from blood. Screening methods are provided for ligands that do not activate other estrogen receptors, and therefore do not have the classical estrogenic effects attributable to these receptors.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: September 3, 2002
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: William C. Mobley, Ronald J. Weigel, Chengbiao Wu, Har Hiu Dawn Lam
  • Activation of novel estrogen receptor supports and neuronal viability and function
    Publication number: 20010016325
    Abstract: Neurological dysfunction is prevented or treated by the administration of ligands that activate the GPR30 receptor. Ligands include, but are not limited to, estrogens and structurally related molecules. In a preferred embodiment, the GPR30 ligand is an orally available drug that can cross into the brain from blood. Of particular interest are ligands that do not activate other estrogen receptors, and therefore do not have the classical estrogenic effects attributable to these receptors.
    Type: Application
    Filed: April 26, 2001
    Publication date: August 23, 2001
    Inventors: William C. Mobley, Ronald J. Weigel, Chengbiao Wu, Har Hui Dawn
  • Method of screening for neuroprotective agents
    Patent number: 6265147
    Abstract: Neurological dysfunction is prevented or treated by the administration of ligands that activate the GPR30 receptor. Ligands include, but are not limited to, estrogens and structurally related molecules. In a preferred embodiment, the GPR30 ligand is an orally available drug that can cross into the brain from blood. Of particular interest are ligands that do not activate other estrogen receptors, and therefore do not have the classical estrogenic effects attributable to these receptors.
    Type: Grant
    Filed: December 1, 1999
    Date of Patent: July 24, 2001
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: William C. Mobley, Ronald J. Weigel, Chengbiao Wu, Har Hiu Dawn Lam